Incyte (INCY) Heads To EADV With New Skin Disease Trial Data

Incyte (NasdaqGS: INCY) plans to present new clinical data on its inflammation and autoimmunity portfolio at the upcoming EADV Congress. The presentation will spotlight updates for Opzelura, ruxolitinib cream, across immune mediated skin diseases studied in recent dermatology trials. Incyte will also feature new findings on povorcitinib, reflecting progress across multiple dermatological indications under investigation. These fresh EADV data drops on Opzelura and povorcitinib only tell part...